EATG » Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Twice-daily tenofovir alafenamide (TAF) plus rifampicin provided similar exposures to once-daily TAF in pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

The results were presented at the 16th European AIDS Conference (EACS 2017), held on 25-27 October 2017 in Milan, Italy.

Read the full report by Polly Clayden, HIV i-Base here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
HIV i-Base
News categories: HIV treatment, Tuberculosis